结直肠癌原发与配对转移肿瘤遗传异质性研究进展

鲁有望,王昆华

doi:10.16288/j.yczz.16-357

遗传 >

2017 , Vol. 39 >Issue 6: 482 - 490

DOI: https://doi.org/10.16288/j.yczz.16-357

综述

结直肠癌原发与配对转移肿瘤遗传异质性研究进展

展开

1. 昆明理工大学医学院,昆明 650500
2. 昆明医科大学第一附属医院胃肠与疝外科,昆明 650500
3. 云南省消化病研究所,昆明 650500

鲁有望，博士研究生，专业方向：环境医学工程。E-mail: youwanglu@163.com|王昆华，教授，主任医师，博士生导师。研究方向：结直肠基因组学及肿瘤异质性。E-mail: wangkunhua_group@163.com

收稿日期: 2016-12-22

修回日期: 2017-04-05

网络出版日期: 2017-04-28

基金资助

云南省卫生厅内设机构云南省消化病研究所项目资助课题(2016NS001,2016NS003,2016NS004);云南省教育厅科学研究项目资助课题(2015J054);云南省教育厅科学研究基金重大专项资助课题(ZD2015010)

收起

Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer

Expand

1. Faculty of Medical , Kunming University of Science and Technology, Kunming 650500, China
2. Department of Gastrointestinal and Hernia surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China
3. Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China

Received date: 2016-12-22

Revised date: 2017-04-05

Online published: 2017-04-28

Supported by

the Foundation of Yunnan Institute of Digestive Disease(2016NS001,2016NS003,2016NS004);the Scientific Research Project of Yunnan Provincial Bureau of Education(2015J054);The Major project of Yunnan Provincial Bureau of Education(ZD2015010)

Fold

摘要

结直肠癌(colorectal cancer, CRC)是我国常见的致死性肿瘤类型之一。根据体细胞突变谱预测抗EGFR单抗治疗疗效已成为转移性结直肠癌(metastatic colorectal cancer, mCRC)治疗的标准步骤。由于临床上转移样本难以获得,只能采用原发肿瘤替代进行检测。原发和配对转移肿瘤间的遗传异质性会导致原发灶取样无法代表转移灶突变谱。目前CRC原发和配对转移肿瘤间遗传异质性程度仍存在争议。本文就CRC原发和配对转移基因组谱的对比研究进行了综述,并讨论了原发与配对转移肿瘤遗传异质性形成的原因及应对策略。

关键词： 结直肠肿瘤; 遗传异质性; 原发灶; 转移灶

本文引用格式

鲁有望,王昆华 . 结直肠癌原发与配对转移肿瘤遗传异质性研究进展[J]. 遗传, 2017 , 39(6) : 482 -490 . DOI: 10.16288/j.yczz.16-357

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer deaths in China. A standard practice in treating metastatic CRC (mCRC) is to predict benefits of the anti-EGFR monoclonal antibody treatment based on the somatic mutation spectrum. Because metastatic samples are difficult to obtain clinically, primary tumors are normally used instead. However, due to the genetic heterogeneity between primary and paired metastatic tumors, primary site biopsy always underrepresents the mutational landscape of metastatic sites. Currently, the extent of genetic heterogeneity between primary and paired mCRC is still under debate. Here, we review comparative studies of primary and matched mCRC and discuss the underlying causes and potential strategies.

Key words： colorectal cancer; genetic heterogeneity; primary site; metastases site

参考文献

[1]

Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014.CA Cancer J Clin, 2014, 64(2): 104-117.

[2]

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.Cell, 1990, 61(5): 759-767.

[3]

Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol, 1998, 15(2): 126-130.

[4]

Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J Clin Pathol, 2014, 67(1): 1-9.

[5]

Sylvester BE, Vakiani E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol, 2015, 6(6): 668-675.

[6]

Miyazaki M, Furuya T, Shiraki A, Sato T, Oga A, Sasaki K. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res, 1999, 59(20): 5283-5285.

[7]

Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut, 2008, 57(7): 941-950.

[8]

Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer, 1999, 25(2): 82-90.

[9]

Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J, Yamagishi H. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer, 2001, 94(5): 623-629.

[10]

Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases-an analysis by comparative genomic hybridization. Genes Chromosomes Cancer, 2005, 43(1): 25-36.

[11]

Vakiani E, Janakiraman M, Shen RL, Sinha R, Zeng ZS, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol, 2012, 30(24): 2956-2962.

[12]

Roessler S, Lin GL, Forgues M, Budhu A, Hoover S, Simpson RM, Wu XL, He P, Qin LX, Tang ZY, Ye QH, Wang XW. Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma. Int J Biol Sci, 2015, 11(1): 88-98.

[13]

Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchro

Options

文章导航

〈

〉

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献